Comprehensive analysis of Baroda BNP Paribas Manufacturing Fund - Reg (G) (44893) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Baroda BNP Paribas Asset Management India Ltd
The investment objective is to generate long-term capital appreciation from a portfolio invested predominantly in equity and equity related securities of companies engaged in the Manufacturing. The Scheme does not guarantee/indicate any returns. There is no assurance that the investment objective of the Scheme will be achieved.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Weak Returns
High Risk
High Expenses
Equity Focused
New Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Outperformance vs benchmark
Market exposure level
Recent performance momentum
Assets under management
Risk-adjusted returns
Fund manager experience
Historical performance consistency
Fund management costs
This fund has outperformed its benchmark by 0.48% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Divis Laboratories Ltd | Pharmaceuticals | 8.12% |
| Reliance Industries Ltd | Refineries | 7.45% |
| Bosch Ltd | Auto Ancillaries | 4.97% |
| Hitachi Energy India Ltd | Capital Goods - Electrical Equipment | 4.22% |
| Mahindra & Mahindra Ltd | Automobile | 3.94% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 3.34% |
| Vedanta Ltd | Mining & Mineral products | 3.08% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 2.94% |
| Astrazeneca Pharma India Ltd | Pharmaceuticals | 2.53% |
| Sumitomo Chemical India Ltd | Agro Chemicals | 2.35% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 4.17% | 20.90% | -2.29% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 3.98% | 20.48% | -2.95% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | -2.23% | 13.57% | 4.61% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | -2.23% | 13.57% | 4.61% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | -2.44% | 13.09% | 3.74% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | -2.44% | 13.09% | 3.74% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | 2.59% | 13.30% | 0.45% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | 2.59% | 13.30% | 0.45% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | 3.31% | 7.85% | -5.66% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 3.11% | 13.18% | -7.36% |
A seasoned investment professional with over 1 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.